These data collectively suggested that EAAT1 at A169G and A329T mutations may be susceptible genes for POAG, and especially for NTG, and that EAAT1/GLAST is a potential therapeutic target for the treatment of glaucoma. This evidence concerns the gene SLC1A3 and open-angle glaucoma.